Clinical Trials Arena

Sign up to our newsletters: us on LinkedIn:

[Clinical Trials Arena @TrialsArena]

Women remain underrepresented in early stage clinical trials. We looked into the misconceptions behind this insidious issue, and the ways the clinical trial ecosystem could break the glass barriers to women's participation in clinical research.
https://t.co/KtcBYAgga6

[Clinical Trials Arena @TrialsArena]

Is pharma shying away from tackling the unmet need in substance use disorders? @ufulti dissects the possible reasons behind this apparent neglect.
https://t.co/5xrcyGAPxT

[Clinical Trials Arena @TrialsArena]

In an exclusive, @OlemaOncology discusses two Phase III trial plans for ER+, HER2- breast cancer. Senior reporter @WillNewton19 has more on how Olema plans to tackle the notoriously tough-to-treat disease with a dual-mechanism oral SERD: https://t.co/Faz8nOZc4i

[Clinical Trials Arena @TrialsArena]

Have you ever thought about recruiting robots for your clinical trial operations? The #clinicaltrials industry is yet to embrace the full advantage of deploying a #bot workforce, @ufulti reports.
https://t.co/tGkLREkxc5

[Clinical Trials Arena @TrialsArena]

In an exclusive, @AshvatthaTx CEO Jeff Cleland delves into plans for a potential trial in #LongCovid after pivoting from acute Covid-19 infections. Read more about the trial's rationale, target population, and potential endpoints:

https://t.co/Jbyx93q6Or

[Clinical Trials Arena @TrialsArena]

For #Psoriasis Awareness Month, we dove into the major upcoming late-stage trial results and completions in plaque psoriasis and psoriatic arthritis. Here’s the major trials you need to follow in the second half of 2022:
https://t.co/LerSDKExPf

[Clinical Trials Arena @TrialsArena]

Axcella $AXLA previews plans for a registrational trial for AXA1125 in #LongCovid, including possible endpoints, on the heels of Phase IIa results announced yesterday. @WillNewton19 reports
https://t.co/qxGMctNZOW

[Clinical Trials Arena @TrialsArena]

A longstanding approach in Alzheimer's disease—the amyloid theory—is under scrutiny after reports of possible image fabrication in multiple journal articles.

In a data-driven analysis, we look at the current state of AD trials based on the amyloid theory: https://t.co/wNpLEVdBYp

[Clinical Trials Arena @TrialsArena]

To commemorate Hepatitis Day, we take a look at GSK's bepirovirsen. While early Phase IIb data shows the candidate has potential to deliver HBV functional cure, experts are still craving for more data. Urte Fultinaviciute (@ufulti) investigates. https://t.co/XxUZnied5g

[Clinical Trials Arena @TrialsArena]

We've updated our #LongCovid trials calendar to bring you four major trial readouts expected in the next year, @WillNewton19 reports: https://t.co/2ntMTQNuwF

And ICYMI, Dr. Fauci discussed the crucial need for standardised endpoints in long Covid trials: https://t.co/TX55F76ZXS

[Clinical Trials Arena @TrialsArena]

With @michaelpollan documentary on #psychedelics landing on #Netflix, it is important to note that this field is yet to prove its value in clinical trials. Read @ufulti feature on the challenges psychedelic clinical trials face. https://t.co/djBk1CqI53

[Clinical Trials Arena @TrialsArena]

There are a variety of noninvasive NASH tests currently available and under investigation—but how can they be optimised? @pharmarey reports.
https://t.co/sxSQvkWcm3

[Clinical Trials Arena @TrialsArena]

Senior reporter @WillNewton19 spoke to @AristeaTx on its Phase III trial plans in palmoplantar pustulosis if the ongoing Phase IIb delivers positive results
https://t.co/it3KINsQdu

[Clinical Trials Arena @TrialsArena]

With all new clinical trial applications for Europe expected to go through the new system from January 2023, CTIS uptake is still slow. Read more for actionable advice for sponsors so they don't get left behind.
https://t.co/3iCwpiUAna

[Clinical Trials Arena @TrialsArena]

Cullinan Oncology gave as an exclusive study design preview of its upcoming Phase IIb trial in non-small cell lung cancer. $CGEM
https://t.co/8V2jj80Eqs

[Drugs for Neglected Diseases initiative @DNDi]

Non-profit organizations such as DNDi are driving efforts to find new therapies for #NTDs — but the support of the pharmaceutical industry is still crucial, says our R&D Director Laurent Fraisse. @PharmaTechFocus @fraisse47 https://t.co/EwKSqeGfQJ

[Clinical Trials Arena @TrialsArena]

While many CROs and sponsors already use eTMF, there are still ways for users to make the most of the technology. There are approaches to lift the burden off clinical trial sites, as well as making sure the system is inspection- or audit-ready. https://t.co/AyfRw3u1FV

[Will Newton @WillNewton19]

I asked Dr. Fauci about the challenges of studying long Covid in clinical trial, and heard his takes on Covid misinformation and public perception:

https://t.co/aeSRlplxvp

[Clinical Trials Arena @TrialsArena]

Senior reporter @WillNewton19 asked Dr Anthony Fauci about the challenges to selecting clinical trial endpoints for long Covid studies during a @NatPress Q&A. Fauci discussed ongoing efforts to study long Covid-19, misinformation, and more:

https://t.co/w3AkFJNrzo

[Clinical Trials Arena @TrialsArena]

We spoke to Liam Paschall (@LPaschall1202) of @Parexel on reasons why transgender and nonbinary individuals may not participate in clinical trials, and “baby steps” the sector can do to help boost engagement in studies https://t.co/lhTbp0YJ6R